Tags

Type your tag names separated by a space and hit enter

In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release.
Eur J Pharm Biopharm. 2023 Feb; 183:13-23.EJ

Abstract

Several formulation strategies have been proposed for oral colon delivery, particularly for the therapy of inflammatory bowel disease (IBD). However, targeting the large intestine remains a challenging goal. The aim of this study was to develop and evaluate a novel type of drug delivery system, which is based on multiple drug release triggers for reliable performance. The system consists of: (i) a drug core, (ii) an inner swellable low-viscosity hydroxypropyl methylcellulose (HPMC) layer, and (iii) an outer film coating based on a Eudragit® S:high-methoxyl (HM) pectin (7:3 w/w) blend, optionally containing chitosan. Convex immediate release tablets (2 or 4 mm in diameter) containing paracetamol or 5-aminosalicylic acid (5-ASA) were coated in a fluid bed. The double-coated tablets exhibited pulsatile release profiles when changing the release medium from 0.1 N HCl to phosphate buffer pH 7.4. Also, drug release was faster in simulated colonic fluid (SCF) in the presence of fecal bacteria from IBD patients compared to control culture medium from tablets with outer Eudragit® S: HM pectin: chitosan coatings. The latter systems showed promising results in the control of the progression of colitis and alteration of the microbiota in a preliminary rat study.

Authors+Show Affiliations

Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: saliha.moutaharrik@unimi.it.Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: alessandra.maroni@unimi.it.University of Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France. Electronic address: christel.neut@univ-lille.fr.University of Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France. Electronic address: carodubu@yahoo.fr.University of Lille, Inserm, CHU Lille, U1286 - INFINITE - Institute for Translational Research in Inflammation, F-59000 Lille, France. Electronic address: laurent.dubuquoy@inserm.fr.Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: anastasia.foppoli@unimi.it.Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: matteo.cerea@unimi.it.Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: luca.palugan@unimi.it.University of Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France. Electronic address: florence.siepmann@univ-lille.fr.University of Lille, Inserm, CHU Lille, U1008, F-59000 Lille, France. Electronic address: juergen.siepmann@univ-lille.fr.Università degli Studi di Milano, Dipartimento di Scienze Farmaceutiche (DISFARM), Sezione di Tecnologia e Legislazione Farmaceutiche "Maria Edvige Sangalli", 20133 Milan, Italy. Electronic address: andrea.gazzaniga@unimi.it.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

36563887

Citation

Moutaharrik, S, et al. "In Vitro and in Vivo Evaluation of a pH-, Microbiota- and Time-based Oral Delivery Platform for Colonic Release." European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, vol. 183, 2023, pp. 13-23.
Moutaharrik S, Maroni A, Neut C, et al. In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. Eur J Pharm Biopharm. 2023;183:13-23.
Moutaharrik, S., Maroni, A., Neut, C., Dubuquoy, C., Dubuquoy, L., Foppoli, A., Cerea, M., Palugan, L., Siepmann, F., Siepmann, J., & Gazzaniga, A. (2023). In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. European Journal of Pharmaceutics and Biopharmaceutics : Official Journal of Arbeitsgemeinschaft Fur Pharmazeutische Verfahrenstechnik E.V, 183, 13-23. https://doi.org/10.1016/j.ejpb.2022.12.013
Moutaharrik S, et al. In Vitro and in Vivo Evaluation of a pH-, Microbiota- and Time-based Oral Delivery Platform for Colonic Release. Eur J Pharm Biopharm. 2023;183:13-23. PubMed PMID: 36563887.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - In vitro and in vivo evaluation of a pH-, microbiota- and time-based oral delivery platform for colonic release. AU - Moutaharrik,S, AU - Maroni,A, AU - Neut,C, AU - Dubuquoy,C, AU - Dubuquoy,L, AU - Foppoli,A, AU - Cerea,M, AU - Palugan,L, AU - Siepmann,F, AU - Siepmann,J, AU - Gazzaniga,A, Y1 - 2022/12/20/ PY - 2022/10/13/received PY - 2022/12/10/revised PY - 2022/12/18/accepted PY - 2022/12/24/pubmed PY - 2022/12/24/medline PY - 2022/12/23/entrez KW - 5-aminosalicylic acid KW - Chitosan KW - Combined time-, pH- and microbiota-dependent approach KW - Eudragit® S KW - Hydroxypropyl cellulose KW - Hydroxypropyl methylcellulose KW - Oral colon delivery KW - Pectin KW - Spray-coating SP - 13 EP - 23 JF - European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V JO - Eur J Pharm Biopharm VL - 183 N2 - Several formulation strategies have been proposed for oral colon delivery, particularly for the therapy of inflammatory bowel disease (IBD). However, targeting the large intestine remains a challenging goal. The aim of this study was to develop and evaluate a novel type of drug delivery system, which is based on multiple drug release triggers for reliable performance. The system consists of: (i) a drug core, (ii) an inner swellable low-viscosity hydroxypropyl methylcellulose (HPMC) layer, and (iii) an outer film coating based on a Eudragit® S:high-methoxyl (HM) pectin (7:3 w/w) blend, optionally containing chitosan. Convex immediate release tablets (2 or 4 mm in diameter) containing paracetamol or 5-aminosalicylic acid (5-ASA) were coated in a fluid bed. The double-coated tablets exhibited pulsatile release profiles when changing the release medium from 0.1 N HCl to phosphate buffer pH 7.4. Also, drug release was faster in simulated colonic fluid (SCF) in the presence of fecal bacteria from IBD patients compared to control culture medium from tablets with outer Eudragit® S: HM pectin: chitosan coatings. The latter systems showed promising results in the control of the progression of colitis and alteration of the microbiota in a preliminary rat study. SN - 1873-3441 UR - https://www.unboundmedicine.com/medline/citation/36563887/In_vitro_and_in_vivo_evaluation_of_a_pH__microbiota__and_time_based_oral_delivery_platform_for_colonic_release_ DB - PRIME DP - Unbound Medicine ER -